Devon scientists reveal 'remarkable' wasp memory

Wasp mothers have stunning brainpower when it comes to feeding their young, according to new research.Digger wasps make a short burrow for each egg, stocking it with food and returning a few days later to provide more.The study by scientists at the University of Exeter revealed mother wasps can remember the locations of up to nine separate nests among hundreds belonging to other females.Experts said they did not yet know how the wasps achieved such "remarkable mental feats."
'Rarely make errors'
Researchers discovered the insects feed their young in age order, adjusting the order if one dies, and they can even delay feeding offspring that had more food at the first visit."Our findings suggest that the miniature brain of an insect is capable of remarkably sophisticated scheduling decisions," said Professor Jeremy Field, from the University of Exeter."We tend to think that something so small couldn't do something so complex."In fact, they can remember where and when they have fed their young and what they fed them in a way that would be taxing even to human brains."
The digger wasps in the study live on heathland in Surrey where they hunt caterpillars on heather plants."Despite nesting in relatively featureless bare sand, often among hundreds of intermingled nests of other females, mothers rarely make errors in revisiting their nests," Mr Field said."Only 1.5% of the 1,293 food deliveries in the study went to other females' nests."

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

BBC News

13 minutes ago

• BBC News

NHS plans to DNA test all babies in England to assess disease risk

Every newborn baby in England will have their DNA mapped to assess their risk of hundreds of diseases, under NHS plans for the next 10 scheme, first reported by the Daily Telegraph, is part of a government drive towards predicting and preventing illness, which will also see £650m invested in DNA research for all patients by Secretary Wes Streeting said gene technology would enable the health service to "leapfrog disease, so we're in front of it rather than reacting to it".It comes after a study analysing the genetic code of up to 100,000 babies was announced in October. The government's 10-year plan for the NHS, which is set to be revealed over the next few weeks is aimed at easing pressure on Department for Health and Social Care said that genomics - the study of genes - and AI would be used to "revolutionise prevention" and provide faster diagnoses and an "early warning signal for disease".Screening newborn babies for rare diseases will involve sequencing their complete DNA using blood samples from their umbilical are approximately 7,000 single gene disorders. The NHS study which began in October only looked for gene disorders that develop in early childhood and for which there are effective newborn babies are only given a heelprick blood test that checks for nine serious conditions, including cystic health secretary said in a statement: "With the power of this new technology, patients will be able to receive personalised healthcare to prevent ill-health before symptoms begin, reducing the pressure on NHS services and helping people live longer, healthier lives."

Daily Mail​

4 hours ago

• Daily Mail​

Erectile dysfunction drug Viagra has surprise new health benefit, scientists find - offering new hope to 3million ageing Britons

A surprising new health benefit has emerged from the sex drug Viagra - which means three million ageing Britons can now also enjoy a harder skull. The little blue tablet was found to increase the production of vital bone cells, preventing back pain and fractures in old age. Sildenafil - also known as Viagra - can help human stem cells transform into osteoblasts which help the human skeleton regenerate as it is completely replaced roughly once every 10 years. As humans get older, they lose more bone than is built, increasing the risk of breaks or osteoporosis, which makes bones brittle and painful. Follow-up tests on mice by Peking University also suggested a prevention of bone loss. Dr Menglong Hu and Dr Likun Wu told MailOnline: 'Our findings offer new insights into the physiological effects of the medicine. 'Sildenafil enhanced stem cell osteogenic differentiation and inhibited bone loss — it may usefully treat osteoporosis.' Viagra was invented as a heart drug in the 1980s before being found to help with erectile dysfunction. Some studies suggest it may also help reduce the risk of dementia. However, the have been cautions over the years that the drug could have some negative side effects, in particular if taken too much. A large quantity of the drug could result in a painful, 'uncomfortably and disproportionately large erection' called a priapism which could go on for hours. Some experts also found regularly taking the common drug may raise the risk of three serious eye conditions. Common side effects may include headaches, hot flushes, nausea, indigestion, dizziness and a stuffy nose. Nearly half of men between the ages of 40 and 70 suffer from erectile dysfunction in the UK - this is more than 4.5 million people. Though, reports suggest Viagra is now even becoming increasingly popular with younger individuals in their 20s and 30s. Last year, it emerged Viagra may help prevent dementia by boosting blood flow in the brain. 'This is the first trial to show that sildenafil gets into the blood vessels in the brain in people with this condition, improving blood flow and how responsive these blood vessels are,'Dr Alastair Webb, a neurologist and study author at Oxford University said.

The Independent

6 hours ago

• The Independent

Weight loss jab could be used to treat migraines

Weight loss jabs could cut the number of migraines sufferers experience by half, research suggests. The drugs, similar to Ozempic and Wegovy, also known as GLP-1 receptor agonists, work by mimicking the natural hormone which regulates blood sugar, appetite and digestion. Researchers have discovered, GLP-1 drug liraglutide, commonly used to treat diabetes, has the potential to significantly reduce migraine frequency. Migraines affect approximately 6 million people in the UK, according to the NHS. Attacks can last for three days causing pain, nausea, vomiting, dizziness and sensitivity to light, sound and smells. Researchers at the Headache Centre of the University of Naples gave 26 adults with obesity and chronic migraines the drug liraglutide. The study presented at the European Academy of Neurology (EAN) Congress 2025, found those who had the drug reported an average of 11 fewer headache days per month. Participants also experienced meaningful improvements in quality of life, work, study, and social functioning within just two weeks of taking the drug. 'Most patients felt better within the first two weeks and reported quality of life improved significantly', said lead researcher Dr Simone Braca. 'The benefit lasted for the full three-month observation period, even though weight loss was modest and statistically non-significant.' Growing evidence has linked subtle increases in intracranial pressure to migraine attacks. It's caused by a rise in the pressure of cerebrospinal fluid – which surrounds the brain and spinal cord. This increase in pressure can happen because of a severe head injury, stroke, a brain tumour or high blood pressure. But GLP-1-receptor agonists such as liraglutide reduce cerebrospinal fluid secretion and have already proved effective in treating idiopathic intracranial hypertension (IIH). Patients in the study were screened to exclude papilledema (optic disc swelling resulting from increased intracranial pressure) and sixth nerve palsy, ruling out IIH. Dr Braca and colleagues believe GLP-1 drugs may reduce the release of CGRP (calcitonin gene-related peptide), a key molecule behind migraines. 'We think that, by modulating cerebrospinal fluid pressure and reducing intracranial venous sinuses compression, these drugs produce a decrease in the release of calcitonin gene-related peptide (CGRP), a key migraine-promoting peptide', Dr Braca said. 'That would pose intracranial pressure control as a brand-new, pharmacologically targetable pathway.' Given liraglutide's established use in type 2 diabetes and obesity, it may represent a promising case of drug repurposing in neurology, study authors said.